REG - Susquehanna Ire. Ltd Shire plc Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Company Limited
RNS Number : 8316LSusquehanna Ireland Ltd31 December 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Susquehanna International Holdings LLC ("SIHLLC")
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
n/a
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Ltd
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
n/a
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
28/12/2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES -Shire Plc
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary Stock ISIN: JP3463000004
ISIN: US8740602052
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
0
(2) Cash-settled derivatives:
0
(4,997,800)
-0.64%
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:
0
(4,997,800)
-0.64%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit (JPY)
ORDINARY
SALE
-700
3751
ORDINARY
SALE
-300
3749
ORDINARY
PURCHASE
6100
3760
ORDINARY
PURCHASE
300
3763
ORDINARY
SALE
-500
3762
ORDINARY
SALE
-1000
3761
ORDINARY
SALE
-3400
3760
ORDINARY
SALE
-1000
3757
ORDINARY
SALE
-100
3756
ORDINARY
SALE
-100
3754
ORDINARY
SALE
-300
3760
ORDINARY
PURCHASE
1700
3771
ORDINARY
PURCHASE
100
3774
ORDINARY
PURCHASE
100
3771
ORDINARY
SALE
-1000
3762
ORDINARY
SALE
-900
3760
ORDINARY
PURCHASE
100
3765
ORDINARY
SALE
-100
3759
ORDINARY
PURCHASE
200
3762
ORDINARY
SALE
-100
3759
ORDINARY
SALE
-100
3759
ORDINARY
PURCHASE
800
3762
ORDINARY
PURCHASE
100
3762
ORDINARY
SALE
-900
3758
ORDINARY
PURCHASE
400
3762
ORDINARY
PURCHASE
400
3762
ORDINARY
PURCHASE
500
3763
ORDINARY
SALE
-1100
3758
ORDINARY
SALE
-200
3759
ORDINARY
PURCHASE
3600
3765
ORDINARY
PURCHASE
200
3767
ORDINARY
SALE
-200
3764
ORDINARY
SALE
-100
3760
ORDINARY
SALE
-2700
3762
ORDINARY
SALE
-800
3761
ORDINARY
PURCHASE
1000
3761
ORDINARY
PURCHASE
100
3756
ORDINARY
PURCHASE
2100
3757
ORDINARY
PURCHASE
300
3759
ORDINARY
PURCHASE
2000
3761
ORDINARY
PURCHASE
5300
3762
ORDINARY
PURCHASE
400
3763
ORDINARY
PURCHASE
700
3765
ORDINARY
PURCHASE
300
3765
ORDINARY
PURCHASE
1100
3764
ORDINARY
PURCHASE
1200
3765
ORDINARY
PURCHASE
200
3766
ORDINARY
SALE
-300
3759
ORDINARY
PURCHASE
400
3761
ORDINARY
PURCHASE
1000
3762
ORDINARY
PURCHASE
600
3761
ORDINARY
SALE
-6000
3755
ORDINARY
SALE
-1700
3753
ORDINARY
SALE
-4400
3751
ORDINARY
SALE
-4300
3750
ORDINARY
PURCHASE
200
3714
ORDINARY
SALE
-200
3716
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
CFD (on ordinary shares)
CFD
Increasing a short position
300,000
3728.0124
JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
31/12/2018
Contact name:
John Kiefel /Olive Fogarty
Telephone number*:
353-1-802-8129
353-1-802-8159
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETWGGBWPUPRGGG
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement